{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:45:41Z","timestamp":1791294341410,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.diabet.2007.07.001","type":"journal-article","created":{"date-parts":[[2007,8,21]],"date-time":"2007-08-21T08:56:51Z","timestamp":1187686611000},"page":"231-244","source":"Crossref","is-referenced-by-count":85,"title":["Type 2\u00a0diabetes mellitus: epidemiology, pathophysiology, unmet needs and\u00a0therapeutical perspectives"],"prefix":"10.1016","volume":"33","author":[{"given":"M.","family":"Virally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-F.","family":"Blickl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-J.","family":"Guillausseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2007.07.001_bib1","doi-asserted-by":"crossref","first-page":"6S9","DOI":"10.1016\/S1262-3636(03)72783-9","article-title":"The burden of type 2 diabetes: are we doing enough?","volume":"29","author":"Zimmet","year":"2003","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2007.07.001_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1262-3636(07)70063-0","article-title":"The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000?","volume":"29","author":"Ricordeau","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib4","article-title":"Treated diabetes in France: what trends between 2000 and 2005?","volume":"33","author":"Kusnik-Joinville","year":"2007","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1464-5491.2006.01877.x","article-title":"Assessment of diabetes screening by general practitioners in France: the EPIDIA Study","volume":"23","author":"Cogneau","year":"2006","journal-title":"Diabet. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib6","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.2337\/dc06-0138","article-title":"Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the US","volume":"29","author":"Schulz","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib7","first-page":"154","article-title":"Pr\u00e9valence de l\u2019ob\u00e9sit\u00e9 de l\u2019adulte en France. La situation en 2000 \u00e0 partir des r\u00e9sultats des \u00e9tudes OBEPI","volume":"63","author":"Charles","year":"2002","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"10.1016\/j.diabet.2007.07.001_bib8","article-title":"\u00c9pid\u00e9miologie des complications li\u00e9es au diab\u00e8te","author":"Simon","year":"2007","journal-title":"Rev. Prat. (Paris)"},{"key":"10.1016\/j.diabet.2007.07.001_bib9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198805123181903","article-title":"Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus","volume":"318","author":"Polonsky","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJM198805123181902","article-title":"Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes","volume":"318","author":"O\u2019Rahilly","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1530\/acta.0.0550278","article-title":"The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus","volume":"55","author":"Cerasi","year":"1967","journal-title":"Acta. Endocrinol. (Kbh)"},{"key":"10.1016\/j.diabet.2007.07.001_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2337\/diabetes.24.1.17","article-title":"Confirmation of impaired early insulin response to glycemic stimulus in non-obese mild diabetes","volume":"24","author":"Fujita","year":"1975","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib13","first-page":"241","article-title":"Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans","volume":"257","author":"Luzi","year":"1989","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.diabet.2007.07.001_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI118846","article-title":"Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs","volume":"98","author":"Rebrin","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabet.2007.07.001_bib15","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2337\/diabetes.47.12.1941","article-title":"Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile","volume":"47","author":"Getty","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2337\/diacare.4.1.85","article-title":"Quantitative and qualitative changes in the early insulin response to glucose in subjects with impaired carbohydrate tolerance","volume":"4","author":"Ratzmann","year":"1981","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM198908103210601","article-title":"Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus","volume":"321","author":"Eriksson","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(89)91306-8","article-title":"Insulin deficiency in non-insulin-dependent diabetics","volume":"1","author":"Temple","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2007.07.001_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2265.1990.tb00915.x","article-title":"Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics","volume":"32","author":"Temple","year":"1990","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.diabet.2007.07.001_bib20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","article-title":"UK Prospective Diabetes Study 16. Overview of 6\u00a0years therapy of type II diabetes: a progressive disease","volume":"44","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/diacare.15.7.815","article-title":"Onset of NIDDM occurs at least 4\u20137\u00a0years before clinical diagnosis","volume":"15","author":"Harris","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diabetes.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1172\/JCI119126","article-title":"Glycation-dependent, reactive oxygen-species-mediated suppression of the insulin gene promoter activity in HIT cells","volume":"99","author":"Matsuoka","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabet.2007.07.001_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJM200008103430607","article-title":"Islet amyloid and type 2 diabetes mellitus","volume":"343","author":"H\u00f6ppener","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s125-002-8248-z","article-title":"Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islets of Japanese type II diabetic patients","volume":"45","author":"Sakuraba","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"\u03b2-cell deficit and increased \u03b2-cell apoptosis in human with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2337\/diabetes.51.1.66","article-title":"\u03b2-cell death and mass in syngenetically transplanted islets exposed to short- and long-term hyperglycemia","volume":"51","author":"Biarnes","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1172\/JCI200319774","article-title":"Superoxide-mediated activation of uncoupling protein 2 causes pancreatic \u03b2-cell dysfunction","volume":"112","author":"Krauss","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"Suppl 1","key":"10.1016\/j.diabet.2007.07.001_bib30","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.2337\/diabetes.53.2007.S136","article-title":"Uncoupling protein 2 and islet function","volume":"53","author":"Chan","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00125-004-1627-9","article-title":"Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients","volume":"48","author":"Anello","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng1732","article-title":"Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes","volume":"38","author":"Grant","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.diabet.2007.07.001_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00125-006-0507-x","article-title":"TCFL2: the biggest story in diabetes genetics since HLA?","volume":"50","author":"Zeggini","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib34","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.2337\/db06-0381","article-title":"Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals","volume":"55","author":"Saxena","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib35","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/bmj.303.6809.1019","article-title":"Fetal and infant growth and impaired glucose tolerance at age 64","volume":"303","author":"Hales","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2007.07.001_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s001250050812","article-title":"In utero undernutrition impairs rat beta-cell development","volume":"40","author":"Garofano","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabet.2007.07.001_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(86)90052-8","article-title":"\u03b2-cell dysfunction, rather than insulin-insensitivy, is the primary defect in familial type 2 diabetes","volume":"2","author":"O\u2019Rahilly","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2007.07.001_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib40","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1210\/jc.85.6.2275","article-title":"Reduced pancreatic \u03b2-cell compensation to the insulin resistance of aging: impact on pro-insulin and insulin levels","volume":"85","author":"Roder","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM199201023260104","article-title":"Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance","volume":"326","author":"Mitrakou","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1001\/jama.273.23.1855","article-title":"Pancreatic beta-cell dysfunction as the primary genetic lesion of NIDDM","volume":"273","author":"Pimenta","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2007.07.001_bib43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00060793-199804000-00010","article-title":"Insulin resistance versus impaired insulin secretion as the genetic basis for type II diabetes","volume":"5","author":"Gerich","year":"1998","journal-title":"Curr. Opin. Endocrinol. Diab."},{"key":"10.1016\/j.diabet.2007.07.001_bib44","first-page":"413","article-title":"Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus","volume":"44","author":"Kruszynska","year":"1996","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib45","first-page":"177","article-title":"Pathogenesis of type II diabetes: metabolic and molecular implications for identifying diabetes genes","volume":"5","author":"De Fronzo","year":"1997","journal-title":"Diab. Rev."},{"issue":"5","key":"10.1016\/j.diabet.2007.07.001_bib46","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.amjmed.2006.01.009","article-title":"Etiology of insulin resistance","volume":"119","author":"Petersen","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1573399054022785","article-title":"Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes","volume":"1","author":"Bouzakri","year":"2005","journal-title":"Curr. Diab. Rev."},{"key":"10.1016\/j.diabet.2007.07.001_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1172\/JCI10583","article-title":"Cellular mechanisms of insulin resistance","volume":"106","author":"Shulman","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabet.2007.07.001_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/scdb.1996.0038","article-title":"Glucose transporters and diabetes","volume":"7","author":"Zierath","year":"1996","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.diabet.2007.07.001_bib50","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1172\/JCI1557","article-title":"Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance","volume":"101","author":"Garvey","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"suppl 2","key":"10.1016\/j.diabet.2007.07.001_bib51","first-page":"33","article-title":"Physiopathologie du diab\u00e8te non insulinod\u00e9pendant","volume":"3","author":"Girard","year":"1997","journal-title":"M\u00e9decine Th\u00e9rapeutique"},{"key":"10.1016\/j.diabet.2007.07.001_bib52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJM199209033271007","article-title":"Carbohydrate metabolism in non-insulin-dependent diabetes mellitus","volume":"327","author":"Dinneen","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib53","first-page":"E67","article-title":"Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes","volume":"290","author":"Woerle","year":"2006","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.diabet.2007.07.001_bib54","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1172\/JCI2720","article-title":"Regulation of endogenous glucose production by glucose per se is impaired in type II diabetes mellitus","volume":"102","author":"Mevorach","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabet.2007.07.001_bib55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1152\/physrev.00032.2003","article-title":"Mouse models of insulin resistance","volume":"84","author":"Nandi","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.diabet.2007.07.001_bib56","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2007.07.001_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.7716547","article-title":"Cloning of the \u03b2-cell high-affinity sulfonylurea receptor: a regulator of insulin secretion","volume":"268","author":"Aguilar-Bryon","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.diabet.2007.07.001_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1126\/science.7716539","article-title":"Pas de deux or more: the sulfonylurea receptors and K+ channels","volume":"268","author":"Philipson","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.diabet.2007.07.001_bib59","article-title":"Sulfonylureas: basic aspects and clinical uses. International Textbook of Diabetes Mellitus","author":"Lebovitz","year":"1992"},{"key":"10.1016\/j.diabet.2007.07.001_bib60","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib61","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2337\/diacare.28.3.544","article-title":"Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2\u00a0years in patients with type 2 diabetes","volume":"28","author":"Tan","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2337\/diacare.12.3.203","article-title":"Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents","volume":"12","author":"Jennings","year":"1989","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2003-44287","article-title":"Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes","volume":"111","author":"Holstein","year":"2003","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib64","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00125-003-1143-3","article-title":"Sulphonylurea action revisited: the postcloning era","volume":"46","author":"Gribble","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heart.90.1.9","article-title":"Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?","volume":"90","author":"Meier","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.diabet.2007.07.001_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/diacare.27.1.201","article-title":"Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS\u00a066","volume":"27","author":"Stevens","year":"2004","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.diabet.2007.07.001_bib67","first-page":"816","article-title":"Sulfonylureas and the risk of myocardial infarction","volume":"55","author":"Thisted","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2007.07.001_bib68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/dmrr.642","article-title":"Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin","volume":"22","author":"Monami","year":"2006","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.diabet.2007.07.001_bib69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/dmrr.498","article-title":"Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French Registry","volume":"21","author":"Danchin","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"suppl 4","key":"10.1016\/j.diabet.2007.07.001_bib70","first-page":"608","article-title":"In-hospital mortality in diabetic patients with acute myocardial infarction (AMI) according to use of sulfonylureas (SU) as chronic pre-admission antidiabetic treatment","volume":"23","author":"Danchin","year":"2006","journal-title":"Diab. UK"},{"key":"10.1016\/j.diabet.2007.07.001_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70257-4","article-title":"Meglitinide analogues: a review of clinical data focused on recent trials","volume":"32","author":"Blickle","year":"2006","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib72","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bjp.0706082","article-title":"Kir6.2-dependent high-affinity repaglinide binding to beta-cell K (ATP) channels","volume":"144","author":"Hansen","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.diabet.2007.07.001_bib73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2337\/diabetes.47.3.345","article-title":"Stimulation of insulin release by repaglinide and gliblenclamide involves both common and distinct processes","volume":"47","author":"Fuhlendorff","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00024677-200302060-00004","article-title":"Pharmacology of the meglitiide analogs: new treatment options for type 2 diabetes mellitus","volume":"2","author":"Malaisse","year":"2003","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.diabet.2007.07.001_bib75","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1055\/s-0029-1212171","article-title":"Preclinical and clinical studies on safety and tolerability of repaglinide","volume":"107","author":"Schatz","year":"1999","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/diacare.22.5.789","article-title":"A double blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients","volume":"22","author":"Damsbo","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib77","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s002280050613","article-title":"A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulfonylureas","volume":"55","author":"Landgraf","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.diabet.2007.07.001_bib78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0168-8227(99)00002-9","article-title":"Repaglinide versus glyburide: a one-year comparison trial","volume":"43","author":"Marbury","year":"1999","journal-title":"Diab. Res. Clin. Pract."},{"key":"10.1016\/j.diabet.2007.07.001_bib79","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/diacare.22.3.463","article-title":"A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group","volume":"22","author":"Wolffenbuttel","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib80","first-page":"28","article-title":"An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus. Muslim subjects during the month of Ramadan","volume":"61","author":"Anwar","year":"2006","journal-title":"Med. J. Malaysia"},{"key":"10.1016\/j.diabet.2007.07.001_bib81","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2006.05.012","article-title":"A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting","volume":"75","author":"Cesur","year":"2007","journal-title":"Diab. Res. Clin. Pract."},{"key":"10.1016\/j.diabet.2007.07.001_bib82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/00003088-200443020-00003","article-title":"Clinical pharmacokinetics of nateglinide. A rapidly-absorbed, short-acting insulinotropic agent","volume":"43","author":"McLeod","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.diabet.2007.07.001_bib83","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2007.07.001_bib84","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1463-1326.2004.00448.x","article-title":"Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents","volume":"7","author":"Goodarzi","year":"2005","journal-title":"Diab. Obes. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib85","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","article-title":"Metformin. New understandings, new uses","volume":"63","author":"Hundal","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2007.07.001_bib86","first-page":"132","article-title":"\u03b1-gluosidase inhibitors as agents in the treatment of diabetes","volume":"2","author":"Lebovitz","year":"1998","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib87","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/diacare.22.6.960","article-title":"A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3\u00a0years (UK Prospective Diabetes Study 44)","volume":"22","author":"Holman","year":"1999","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2006.09.007","article-title":"Thiazolidinediones for the treatment of type 2 diabetes","volume":"18","author":"Elte","year":"2007","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib89","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00129784-200202030-00002","article-title":"Effects of the thiazolidinediones on cardiovascular risk factors","volume":"2","author":"Gilling","year":"2002","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.diabet.2007.07.001_bib90","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2007.07.001_bib91","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib92","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/diacare.25.4.708","article-title":"A prospective randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone","volume":"25","author":"Khan","year":"2002","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib93","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2007.07.001_bib94","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3949\/ccjm.73.4.390","article-title":"Do thiazolidinediones cause heart failure? A critical review","volume":"73","author":"Wilson","year":"2006","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.diabet.2007.07.001_bib95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3132\/dvdr.2005.010","article-title":"Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?","volume":"2","author":"Patel","year":"2005","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.diabet.2007.07.001_bib96","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00024677-200302010-00004","article-title":"Weight effect of current and experimental drugs for diabetes mellitus. From Promotion to Alleviation of Obesity","volume":"2","author":"Purnell","year":"2003","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.diabet.2007.07.001_bib97","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"(Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trail","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2007.07.001_bib98","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","article-title":"Bone is a target for the antidiabetic compound rosiligtazone","volume":"145","author":"Rzonca","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2007.07.001_bib99","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1210\/en.2006-1587","article-title":"Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone","volume":"148","author":"Lazarenko","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2007.07.001_bib100","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","article-title":"Thiazolidinedione use and bone loss in older diabetic adults","volume":"91","author":"Schwartz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00006982-200605000-00011","article-title":"Diabetic macular edema associated with glitazone use","volume":"26","author":"Ryan","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.diabet.2007.07.001_bib102","first-page":"86","article-title":"P\u00efoglitazone. A review of its use in type 2 diabetes mellitus","volume":"66","author":"Waugh","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2007.07.001_bib103","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1345\/aph.1H609","article-title":"Elevated creatine kinase and myalgia in a patient taking rosiglitazone","volume":"41","author":"Kennie","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.diabet.2007.07.001_bib104","first-page":"643","article-title":"Type 2 diabetes treatment: French recommendations for good practice AFSSAPS \u2013 HAS. 2006","volume":"32","year":"2006","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib105","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.clpt.6100156","article-title":"Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus rationale and specific agents","volume":"81","author":"Cefalu","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.diabet.2007.07.001_bib106","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/dc05-2179","article-title":"Contributions of \u03b2-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdu-Ghani","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib107","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and non-diabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib108","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.diabet.2007.07.001_bib109","first-page":"A2","article-title":"Inhibition of DPP8\/9 results in toxicity in preclinical studies: potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of type 2 DM","volume":"53","author":"Lankas","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/13543784.14.1.57","article-title":"Therapeutic assessment of GLP-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential anti-diabetic drugs","volume":"14","author":"Mentlein","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.diabet.2007.07.001_bib111","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2337\/diabetes.47.8.1253","article-title":"Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide","volume":"47","author":"Pederson","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib112","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00125-005-1707-5","article-title":"Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes","volume":"48","author":"Mest","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-2006-944546","article-title":"Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes","volume":"38","author":"Pratley","year":"2006","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.diabet.2007.07.001_bib114","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib115","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1463-1326.2005.00539.x","article-title":"Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response","volume":"7","author":"Ristic","year":"2005","journal-title":"Diabetes Obes. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2007.07.001_bib116","first-page":"120","article-title":"Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)","volume":"55","author":"DeJager","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2007.07.001_bib117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/dc06-1815","article-title":"Comparison of vildagliptin and rosiglitazone monotherapy in patients with type","volume":"30","author":"Rosenstock","year":"2007","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib118","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib119","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","article-title":"Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12\u00a0weeks in patients with type 2 diabetes","volume":"61","author":"Scott","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.diabet.2007.07.001_bib120","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib121","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.28.8.1936","article-title":"Improved meal related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1\u00a0year","volume":"28","author":"Ahren","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2007.07.001_bib122","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1463-1326.2006.00698.x","article-title":"Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes","volume":"9","author":"Rosenstock","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib123","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","article-title":"Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes","volume":"50","author":"Fonseca","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2007.07.001_bib124","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabet.2007.07.001_bib125","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diab. Care"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363607001425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363607001425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T05:56:03Z","timestamp":1556776563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363607001425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1262363607001425"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2007.07.001","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}